CIK 0001800315 · Non-accelerated filer<br>Smaller reporting company
Damora Therapeutics, Inc.
Sign in to watch- Ticker
- DMRA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 371957007
- Phone
- (781) 281-9020
- Business address
- 100 FIFTH AVENUE, SUITE 700, WALTHAM, MA, 02451
- Former names
- Galecto, Inc., Galecto Inc.
- Open-market buys, last 90 days
- $252,875
- in 1 filing
- Open-market sales, last 90 days
- $0
- in 0 filings
Net +$252,875. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2020-11-02 | Novo Holdings A/S 10% owner | Conversion | +2,164,458 | 2,164,458 | ||
| 2020-11-02 | Novo Holdings A/S 10% owner | Purchase | +333,333 | $15.00 | $5.0M | 2,497,791 |
| 2020-11-02 | Novo Holdings A/S 10% owner | Conversion · SERIES B-1 PREFERRED STOCK | −25,562 | 0 | ||
| 2020-11-02 | Novo Holdings A/S 10% owner | Conversion · SERIES B-2 PREFERRED STOCK | −15,833 | 0 | ||
| 2020-11-02 | Novo Holdings A/S 10% owner | Conversion · SERIES B-3 PREFERRED STOCK | −63,333 | 0 | ||
| 2020-11-02 | Novo Holdings A/S 10% owner | Conversion · SERIES B-4 PREFERRED STOCK | −66,666 | 0 | ||
| 2020-11-02 | Novo Holdings A/S 10% owner | Conversion · SERIES C-1 PREFERRED STOCK | −133,991 | 0 | ||
| 2020-11-02 | Novo Holdings A/S 10% owner | Conversion · SERIES C-2 PREFERRED STOCK | −194,666 | 0 | ||
| 2020-11-02 | Novo Holdings A/S 10% owner | Conversion · SERIES C-4 PREFERRED STOCK | −181,688 | 0 | ||
| 2020-11-02 | Novo Holdings A/S 10% owner | Conversion · SERIES C-5 PREFERRED STOCK | −51,911 | 0 | ||
| 2020-11-02 | Novo Holdings A/S 10% owner | Conversion · SERIES D PREFERRED STOCK | −98,930 | 0 | ||
| 2020-11-02 | GOLDFISCHER CARL Director | Conversion | +9,587 | 9,587 | ||
| 2020-11-02 | GOLDFISCHER CARL Director | Conversion | +1,020,036 | 1,020,036 | ||
| 2020-11-02 | GOLDFISCHER CARL Director | Conversion | +19,432 | 19,432 | ||
| 2020-11-02 | GOLDFISCHER CARL Director | Conversion · Series C-3 Preferred Stock | −392,367 | 0 | ||
| 2020-11-02 | GOLDFISCHER CARL Director | Conversion · Series C-3 Preferred Stock | −7,475 | 0 | ||
| 2020-11-02 | GOLDFISCHER CARL Director | Conversion · Series D Preferred Stock | −3,688 | 0 | ||
| 2020-11-02 | Pedersen Anders Chief Operating Officer | Conversion | +3,746 | 3,746 | ||
| 2020-11-02 | Pedersen Anders Chief Operating Officer | Conversion · Series C-1 Preferred Stock | −1,441 | 0 | ||
| 2020-11-02 | ORBIMED ADVISORS LLC Director | Conversion | +2,055,824 | 2,055,824 |
Page 9 of 12 · 227 trades